Vagus Nerve Stimulator for Autism and Other Developmental Disorders

Last updated: February 6, 2024
Sponsor: New York State Institute for Basic Research
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cerebral Palsy

Learning Disorders

Asperger's Disorder

Treatment

Vagus Nerve Stimulation

Clinical Study ID

NCT06259201
NYInstitute
  • Ages 12-40
  • All Genders

Study Summary

The goal of this flexible single-subject design vagus nerve stimulation (VNS) study is to examine the behavioral, cognitive, and biorhythmic effects of VNS in children and adults with autism and developmental disabilities. The main aims are:

  • Pilot the creation of a profile for those who will respond to VNS with the long-term goal of designing clinical trials.

  • Examine the effects of VNS on a broad range of symptoms.

Participants will select between 1, 2, or 3 months of daily VNS treatment and complete study visits each month.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Children and adults aged 12-40 with intellectual and developmental disability (IDD)and/or autism spectrum disorder (ASD). Participants who are decisionally-impaired willbe eligible with assent.
  2. Able to tolerate wearing an Apple Watch, EEG, and sit for a neurocognitive test
  3. Be on a stable dose of psychotropic medication for at least one month prior toenrollment
  4. Agree not to initiate new or change existing medications or behavior intervention

Exclusion

Exclusion Criteria:

  1. Have an active implantable medical device (e.g., pacemaker, implanted hearing aid,etc.) or a metallic device, such as a stent, bone plate, or bone screw
  2. Have a comorbid physical or psychiatric disorder which would disrupt ability totolerate vagal stimulation or comply with study demands (e.g., insulin dependentdiabetes, bipolar, etc.)
  3. Vagus nerve lesion, damage, or structural abnormality (e.g., lymphadenopathy,neoplasm, previous surgery), or pain (e.g., dysesthesia, neuralgia and/or cervicalgia)
  4. Current or past history of neurological disorders or trauma, including uncontrolledepilepsy and head injury.
  5. Current or recent (within 12 months) participation in a clinical trial of a drug or amedical device.
  6. Use of drugs (within 4 weeks) that affect the autonomic nervous system (beta blockers,beta stimulant, etc.).
  7. Use of marijuana (including medical marijuana) for any indication
  8. Any condition per the investigators' clinical judgment that precludes participation inthe study (e.g., pregnancy).
  9. Lack of capacity to consent and without a legally authorized representative (LAR) whois a parent, spouse, or an adult child.
  10. Living in a residential program (e.g., group home)
  11. Wards of state

Study Design

Total Participants: 75
Treatment Group(s): 1
Primary Treatment: Vagus Nerve Stimulation
Phase:
Study Start date:
March 01, 2024
Estimated Completion Date:
December 31, 2026

Study Description

Intellectual and developmental disabilities (IDD) cover a wide variety of disorders. Although we know the causes of some of the disorders and some of them could even be prevented (e.g., lead exposure), most causes remain unknown. Without having a clear understanding of the causes, prevention is very difficult to achieve. Previous studies have shown abnormal autonomic nervous system (ANS) regulations in young children with autism spectrum disorder (ASD) and these abnormalities are also observed during sleep. ANS is the part of the nervous system that controls the unconscious bodily functions, such as breathing, heart beating, and digestion.

The vagus nerve strongly influences these autonomic functions including digestion, breathing, heart rate variability, and metabolic function and central nervous system (CNS) activity that affect mood, pain, stress management, sleep, and even memory and cognitive functions. The vagal influence over neurotransmitter release has been implicated in the regulation of inflammation and immune cell activity.

Here, we are using a non-invasive vagus nerve stimulator to monitor changes in cognitive function and other symptoms in people with IDD, both with and without ASD. The device is FDA-approved for migraine and cluster headaches in people 12 years and older. VNS activates the vagus nerve with mild electrical stimulation through the skin.

Rather than embarking on a rigorously designed study, we will conduct a series of single-subject studies that reflects each participant's symptoms. We will select the most appropriate dependent variables based on each person's symptom presentation.

Connect with a study center

  • New York State Psychiatric Institute

    New York, New York 10032
    United States

    Site Not Available

  • New York State Institute for Basic Research

    Staten Island, New York 10314
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.